Lilly's CYRAMZA(R) (ramucirumab) receives fourth FDA approval
Eli Lilly has received its fourth FDA approval for CYRAMZAź (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for treatment of patients with mCRC. April 24, 2015